Clene to Provide CNM-Au8® ALS Program Update

Core Viewpoint - Clene Inc. is set to provide an update on its CNM-Au8 program for ALS during a webcast on December 3, 2025, highlighting its focus on neurodegenerative diseases [1][2]. Company Overview - Clene Inc. is a late clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS, Parkinson's disease, and multiple sclerosis [3]. - The company operates from Salt Lake City, Utah, with research and development as well as manufacturing facilities located in Maryland [3]. Product Information - CNM-Au8 is an investigational first-in-class therapy designed to improve the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway while reducing oxidative stress [3]. - CNM-Au8 is an oral suspension of gold nanocrystals aimed at restoring neuronal health and function by increasing energy production and utilization, thereby promoting neuroprotection and remyelination [4].